Discoid Lupus Erythematosus
Conditions
Keywords
Discoid Lupus Erythematosus, Immune System Diseases, Lupus Erythematosus, Cutaneous, Skin Diseases, Connective Tissue Diseases
Brief summary
A Phase 2, double-blind, randomized, placebo-controlled parallel-group study to evaluate the efficacy and safety of daxdilimab in participants with moderate-to-severe active primary Discoid Lupus Erythematosus (DLE) refractory to standard of care.
Detailed description
Approximately 72 participants will be enrolled to receive daxdilimab or placebo administered subcutaneously once every four weeks (Q4W) from Day 1 to Week 20. The maximum trial duration per participant is approximately 36 weeks including screening, the 24 weeks for the treatment period where participants will receive daxdilimab or placebo, and approximately 8 weeks for the follow-up period. Safety evaluations will be performed regularly throughout the course of the study. Acquired from Horizon in 2024.
Interventions
DRUGPlacebo
Placebo will be administered subcutaneously as two injections for each dose.
DRUGDaxdilimab
Daxdilimab will be administered subcutaneously as two injections for each dose.
Sponsors
Amgen
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * Willing and able to understand and provide written informed consent. * Willing and able to comply with the prescribed treatment protocol and evaluations for the duration of the trial. * A diagnosis of DLE for ≥ 6 months prior to screening supported by a history of: 1. A biopsy or 2. a clinical feature score of ≥ 7 on the DLE Classification Criteria (DLECC) scale. * Currently active discoid lupus with all the following: 1. Digital photography adjudicated with central reading to confirm a currently active discoid disease lesion. 2. CLASI-A score ≥ 8 related to discoid lesions at Baseline. * Treatment refractory DLE defined as active disease despite current or historical treatment with a systemic treatment. * Females are eligible to participate if they are not pregnant or breastfeeding, and meet the contraceptive/barrier requirement(s). * Males are eligible to participate if they agree to the contraceptive/barrier requirement(s). * Vaccination status should be up to date per local standards. Key
Exclusion criteria
* Participation in another clinical study with an investigational drug within 4 weeks prior to Randomization or within 5 published half-lives, whichever is longer. * Any condition that, in the opinion of the Investigator, would interfere with evaluation of the investigational product (IP) or interpretation of participant safety or trial results. * Weight \> 160 kg (352 pounds) at Screening. * History of allergy, hypersensitivity reaction, or anaphylaxis to any component of the IP or to a previous monoclonal antibody (mAb) or human immunoglobin (Ig) therapy. * Breastfeeding or pregnant women or women who intend to become pregnant anytime from signing the informed consent form (ICF) through 6 months after receiving the last dose of IP. * Splenectomy. * Spontaneous or induced abortion, still or live birth, or pregnancy ≤ 4 weeks prior to screening through randomization. * History of clinically significant cardiac disease including unstable angina, myocardial infarction, congestive heart failure within 6 months prior to Randomization; arrhythmia requiring active therapy, except for clinically insignificant extra systoles, or minor conduction abnormalities. * History of cancer within the past 5 years, except as follows: * Cutaneous basal cell or squamous cell carcinoma treated with curative therapy. * Any underlying condition that in the opinion of the Investigator significantly predisposes the participant to infection. * Known history of a primary immunodeficiency or an underlying condition, such as known human immunodeficiency virus (HIV) infection, or a positive result for HIV infection per central laboratory. * Participants with positive hepatitis B serologic test results. * All participants will undergo testing for hepatitis C antibody (HCVAb) during Screening. * Participants who are HCVAb positive will be reflex tested for hepatitis C virus (HCV) RNA and if HCV RNA is positive, the participant is not eligible for the study. * Active tuberculosis (TB), or a positive interferon-gamma release assay (IGRA) test at screening, unless documented history of appropriate treatment for active or latent TB. Participants with an indeterminate IGRA test result can repeat the test, but if the repeat test is also indeterminate, they will be excluded. * Any severe herpes virus family infection (including Epstein-Barr virus, cytomegalovirus (CMV)) at any time prior to Randomization, including, but not limited to, disseminated herpes, herpes encephalitis, recent recurrent herpes zoster (defined as 2 episodes within the last 2 years), or ophthalmic herpes. * Any herpes zoster, CMV, or Epstein-Barr virus infection that was not completely resolved 12 weeks prior to Randomization. * Opportunistic infection requiring hospitalization or parenteral antimicrobial treatment within 2 years prior to Randomization. * Any acute illness or evidence of clinically significant active infection on Day 1. * Participants who have COVID-19 or other significant infection, or in the judgment of the Investigator, may be at a high risk of COVID-19 or its complications should not be randomized. * Systemic lupus erythematosus defined by fulfilling 2020 American College of Rheumatology/European Alliance of Associations for Rheumatology criteria for systemic lupus erythematosus (SLE). * Current diagnosis of a systemic connective tissue disease. * Current inflammatory skin disease other than DLE, that, in the opinion of the Investigator, could interfere with the inflammatory skin assessments and confound the disease activity assessments. * Exposure to an experimental drug either 30 days, 5 half-lives of the agent, or twice the duration of the biological effect of the agent, whichever is longer, prior to Randomization and through the final trial visit. * Receipt of a live-attenuated vaccine within 4 weeks prior to Randomization.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean Change in Cutaneous Lupus Erythematosus Disease and Severity Index-Activity (CLASI-A) Score from Baseline to Week 24 | Baseline to Week 24 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants who Achieve 0 or 1 on the Cutaneous Lupus Activity-investigator's Global Assessment (CLA-IGA) scale at Week 24 | Week 24 | CLA-IGA will be assessed by 5-point Likert Scale (0-4). |
| Percentage of Participants who Achieve a ≥ 50% Reduction in CLASI-A Score from Baseline at Week 24 | Baseline to Week 24 | — |
| Mean Change in the Score of Activity and Damage in Discoid Lupus Erythematosus (SADDLE) from Baseline to Week 24 | Baseline to Week 24 | — |
| Serum Concentration of Daxdilimab Over Time | Day 1 to Week 24 | — |
| Percentage of Participants who Develop Anti-Drug Antibodies (ADA) | Day 1 to Week 32 | — |
| Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) | Day 1 to SFU2 (Week 32) | AEs, Serious AEs (SAEs) and AEs of Special Interest (AESIs) will be monitored. An AE is any untoward medical occurrence in a clinical trial participant, temporally associated with the use of trial intervention, whether or not considered related to the trial intervention. An SAE is defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria listed: 1. Results in death 2. Is life-threatening. An AESI is an AE of scientific and medical interest specific to understanding of the IP and may require close monitoring and collection of additional information by the Investigator. An AESI may be serious or nonserious. |
Countries
Argentina, Brazil, Bulgaria, Canada, Czechia, Denmark, France, Germany, Greece, Poland, United States
Contacts
STUDY_DIRECTORMD
Amgen
Outcome results
None listed